Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 8/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | DRD1 | P21728 | 2/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14500659 | 0.94 | CACNA1B (0.47) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL6929475 | 0.94 | CACNA1B (0.52) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL6931100 | 0.94 | CACNA1B (0.49) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL6931083 | 0.94 | CACNA1B (0.56) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL6929235 | 0.91 | CACNA1B (0.49) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL6929484 | 0.87 | CACNA1B (0.56) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL4502482 | 0.87 | CACNA1B (0.59) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL6929379 | 0.85 | CACNA1B (0.49) | CACNA1BADRA1ACACNA1CCASRMEN1 | |
| SCHEMBL6930161 | 0.83 | CACNA1B (0.46) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C | |
| SCHEMBL7750506 | 0.83 | CACNA1B (0.46) | CACNA1BADRA1AADRA2ASLC6A3ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459430-B2 | Methods of using ziconotide to treat overactive bladder | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459430-B2 | Methods of using ziconotide to treat overactive bladder | DYNOGEN PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7223754-B2 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| WO-2005000285-A2 | METHODS OF TREATING NON-INFLAMMATORY GASTROINTESTINAL TRACT DISORDERS USING Cav2.2 SUBUNIT CALCIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-6610717-B2 | Selectively inhibits action of N-type calcium channel; treatment of ischemic cerebrovascular disorders caused by cerebral infarction or intracerebral bleeding, Alzheimer's disease, AIDS related dementia, Parkinson's disease | AJINOMOTO CO., INC. (JP) | 2003-08-26 | — | — | US | disclosed |
| US-20020193605-A1 | New dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-12-19 | — | — | US | disclosed |
| EP-1191022-A1 | NOVEL DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105785-A1 | Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators | CACNB2, RYR2, FABP2 | CACNA1B 7/4885ADRA1A 1205/4885ADRA2A 309/4885 |
| US-20020193605-A1 | New dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CACNA1B 1/4885ADRA1A 390/4885ADRA2A 349/4885 |
| US-20070066597-A1 | Thiazolidinone, oxazolidinone, and imidazolone derivatives for treating lower urinary tract and related disorders | RYR2, CACNB2, CACNA1I | CACNA1B 10/4885ADRA1A 1004/4885ADRA2A 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.